Lannett Company Inc (LCI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lannett Company Inc (LCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10032
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lannett Company Inc (Lannett) is a pharmaceutical company. It develops, manufactures and distributes generic prescription pharmaceutical products in tablet, capsule and oral liquid forms. The company offers generic pharmaceuticals for medical indications such as antibiotic, cardiovascular, central nervous systems, gallstone, gastrointestinal, glaucoma, gout, migraine, muscle relaxant, obesity, pain management, respiratory, thyroid deficiency and urinary. Lannett also offers laboratory services, product formulation and development services, granulation, blending, encapsulation, compression, coating and packaging solid dosage forms. The company sells its pharmaceutical products across the US to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private-label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations and health maintenance organizations. Lannett is headquartered in Philadelphia, Pennsylvania, the US.

Lannett Company Inc (LCI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lannett Company Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lannett Company Inc, Medical Devices Deals, 2012 to YTD 2018 11
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Lannett Company Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Lannett Acquires Portfolio of Generic Products from Endo International 13
Lannett to Acquire Estradiol Tablets and Selegiline Hydrochloride Capsules 14
Partnerships 15
Lannett Enters into Distribution Agreement with Aralez Pharma 15
Lannett to Form Partnership with YiChang HEC ChangJiang Pharmaceutical 16
Lannett Enters into Co-Marketing Agreement with Sunshine Lake 17
Panacea Biotec Enters Into R&D Agreement With Kremers Urban For Generic Drugs 18
Licensing Agreements 19
Lannett Amends Licensing Agreement with Andor Pharma 19
Equity Offering 20
Lannett Company Files Registration Statement to Raise Funds through Public Offering of Securities 20
Lannett Completes Public Offering Of Shares For US$76.5 Million 21
Lannett Files Shelf Registration Statement For Public Offering Of Securities For Up To US$64 Million 22
Acquisition 23
Lannett Company Plans to Sell Cody Laboratories 23
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 24
Lannett Acquires Silarx Pharma for USD42 Million 26
Lannett Company Inc – Key Competitors 27
Lannett Company Inc – Key Employees 28
Lannett Company Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 20, 2018: Lannett announces preliminary fiscal 2018 fourth-quarter and full-year financial results 30
May 07, 2018: Lannett Announces Fiscal 2018 Third-Quarter Financial Results 31
Feb 07, 2018: Lannett Announces Fiscal 2018 Second-Quarter Financial Results; Reports Record Revenues, Strong Earnings 32
Nov 06, 2017: Lannett Reports Solid Fiscal 2018 First-Quarter Financial Results, Significantly Increases Fiscal 2018 Guidance 33
Aug 23, 2017: Lannett Reports Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Provides Guidance For Fiscal 2018 34
Aug 08, 2017: Lannett Announces Preliminary Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Comments On Fiscal 2018 Outlook 35
May 02, 2017: Lannett Reports Fiscal 2017 Third-Quarter Financial Results 36
Feb 01, 2017: Lannett Reports Fiscal 2017 Second-Quarter Financial Results 37
Corporate Communications 38
Apr 30, 2018: Lannett Announces Changes To Board Of Directors 38
Apr 20, 2018: Lannett Names Maureen Cavanaugh Senior Vice President And Chief Commercial Operations Officer 39
Jan 18, 2018: Lannett Appoints Timothy C. Crew As Board Of Directors 40
Dec 21, 2017: Lannett Appoints Timothy C. Crew As CEO 41
Sep 25, 2017: Lannetts Board Of Directors Initiates CEO Search 42
Jul 17, 2017: Lannett Appoints Samuel H. Israel As General Counsel 43
Jun 20, 2017: Lannett Names Patrick G. LePore To Board of Directors 44
Legal and Regulatory 45
Nov 01, 2017: Lannett Comments On Amended Civil Complaint 45
Product News 46
Jul 23, 2018: Lannett Announces Multiple Product Launches 46
06/26/2017: Lannett Receives Approval For Additional Dosage Strengths Of Hydrocodone Bitartrate And Acetaminophen Tablets USP 47
Other Significant Developments 48
Jun 29, 2018: Lannett Announces Restructuring Plan Of Cody Laboratories Subsidiary 48
Mar 12, 2018: Lannett Adds New Revenue Streams, Announces Agreements With Three Strategic Alliance Partners 49
Mar 30, 2017: Lannett Voluntarily Pays Down Additional $25 Million Of Revolving Credit Facility 50
Feb 07, 2017: Lannett Announces Successful Completion Of ERP System Extraction 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Lannett Company Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lannett Company Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lannett Company Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Lannett Company Inc, Medical Devices Deals, 2012 to YTD 2018 11
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Lannett Acquires Portfolio of Generic Products from Endo International 13
Lannett to Acquire Estradiol Tablets and Selegiline Hydrochloride Capsules 14
Lannett Enters into Distribution Agreement with Aralez Pharma 15
Lannett to Form Partnership with YiChang HEC ChangJiang Pharmaceutical 16
Lannett Enters into Co-Marketing Agreement with Sunshine Lake 17
Panacea Biotec Enters Into R&D Agreement With Kremers Urban For Generic Drugs 18
Lannett Amends Licensing Agreement with Andor Pharma 19
Lannett Company Files Registration Statement to Raise Funds through Public Offering of Securities 20
Lannett Completes Public Offering Of Shares For US$76.5 Million 21
Lannett Files Shelf Registration Statement For Public Offering Of Securities For Up To US$64 Million 22
Lannett Company Plans to Sell Cody Laboratories 23
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 24
Lannett Acquires Silarx Pharma for USD42 Million 26
Lannett Company Inc, Key Competitors 27
Lannett Company Inc, Key Employees 28
Lannett Company Inc, Other Locations 29
Lannett Company Inc, Subsidiaries 29

List of Figures
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lannett Company Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Lannett Company Inc (LCI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Russian Aircraft Corporation MiG JSC:企業の戦略・SWOT・財務情報
    Russian Aircraft Corporation MiG JSC - Strategy, SWOT and Corporate Finance Report Summary Russian Aircraft Corporation MiG JSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Haplogen GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Haplogen GmbH (Haplogen) is a biopharmaceutical company that improves human health by fighting against infectious diseases such as common cold, dengue fever, influenza and hepatitis C. The company utilizes its proprietary genetics technology platform to identify novel pathogen host factors a …
  • Repsol SA Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Repsol SA Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Repsol SA (Repsol) is an integrated oil and gas company. It has presence across the entire value chain: exploration and production, transformation, development and marketing of energy. The company’s upstre …
  • Shenzhen Neptunus Interlong Bio-Technique Co Ltd (8329):企業の財務・戦略的SWOT分析
    Summary Shenzhen Neptunus Interlong Bio-Technique Co Ltd (Neptunus) manufactures and distributes gene engineering drugs and preventive biological products. The company’s products include recombinant human interferon a-2b injection, used to treat hepatitis and cancers; recombinant human interleukin-2 …
  • Cerus Corp (CERS)-医療機器分野:企業M&A・提携分析
    Summary Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusion-transmitted infections by inactivating a wide r …
  • EBS Technologies GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary EBS Technologies GmbH (EBS) is a medical device company that develops stimulation system for visual field effect. The company offers Eyetronic Therapy, which has been developed for patients suffering from a progressive visual field loss due to glaucoma and other diseases of the optic nerve. …
  • BASF SE (BAS):製薬・医療:M&Aディール及び事業提携情報
    Summary BASF SE (BASF) is a chemical company, which carries out the research and development (R&D), production, marketing and sales of chemicals, plastics, crop protection products, and performance products. Its product line comprises solvents, adhesives, surfactant, organic chemicals, fuel additive …
  • Versum Materials, Inc.:企業の戦略的SWOT分析
    Versum Materials, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Quaterra Resources Inc (QTA):企業の財務・戦略的SWOT分析
    Summary Quaterra Resources Inc (Quaterra Resources) is a copper exploration company that acquires and operates copper projects. The company's activities include acquisition, exploration and development of gold, silver, and copper deposits in Canada. Its projects comprise Quaterra’s Yerington Copper …
  • Aker Solutions ASA:企業の戦略・SWOT・財務分析
    Aker Solutions ASA - Strategy, SWOT and Corporate Finance Report Summary Aker Solutions ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Endonovo Therapeutics Inc (ENDV):医療機器:M&Aディール及び事業提携情報
    Summary Endonovo Therapeutics Inc (Endonovo Therapeutics) is a commercial stage development company that offers non-invasive medical devices and equipment. The company’s products include Electroceutical Therapy a FDA-Cleared for the palliative treatment of pain and post-surgical edema and CE Marked …
  • AcelRx Pharmaceuticals Inc (ACRX)-医療機器分野:企業M&A・提携分析
    Summary AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes novel therapies for the treatment of pain. The company’s lead product candidate, DSUVIA (known as ARX-04 outside the US), is a single sufentanil sublingual tablet for the treatment of …
  • Stanwell Corp Ltd:企業の戦略的SWOT分析
    Stanwell Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Willis Towers Watson Public Ltd Co:戦略・SWOT・企業財務分析
    Willis Towers Watson Public Ltd Co - Strategy, SWOT and Corporate Finance Report Summary Willis Towers Watson Public Ltd Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Plexus Corp (PLXS):企業の財務・戦略的SWOT分析
    Plexus Corp (PLXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Diana S.A.S.:企業の戦略・SWOT・財務分析
    Diana S.A.S. - Strategy, SWOT and Corporate Finance Report Summary Diana S.A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Verisante Technology Inc (VRS)-医療機器分野:企業M&A・提携分析
    Summary Verisante Technology Inc (Verisante), develops and commercializes products for the early detection of all forms of skin cancer. The company’s key product offerings include Verisante Aura, Verisante Core and Verisante MSI Camera. The Verisante Aura is used for skin cancer detection, and Veris …
  • Takeda Pharmaceuticals USA Inc-製薬・医療分野:企業M&A・提携分析
    Summary Takeda Pharmaceuticals USA Inc (TPUSA), formerly Takeda Pharmaceuticals North America Inc, a subsidiary of Takeda Pharmaceutical Company Ltd, is a developer, manufacturer and distributor of pharmaceutical drugs. The company’s products include pioglitazone and glimepiride, lubiprostone, piogl …
  • Enerjisa Enerji Uretim AS:電力:M&Aディール及び事業提携情報
    Summary Enerjisa Enerji Uretim A.S. (Enerjisa Enerji), a subsidiary of Enerjisa Enerji A.S, is an energy utility. The company generates electricity from natural gas, lignite coal, hydro, and wind sources. It owns and operates wind plants such as Canakkale in Mahmudiye, Dagpazari in Mut, and Balikesi …
  • The Straits Trading Co Ltd:企業の戦略・SWOT・財務情報
    The Straits Trading Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The Straits Trading Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆